- Home
- ALXO vs ENTX Comparison
ALXO vs ENTX Comparison
Compare ALXO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ENTX
- Stock Information
- Founded
- ALXO 2015
- ENTX 2010
- Country
- ALXO United States
- ENTX Israel
- Employees
- ALXO N/A
- ENTX N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALXO Health Care
- ENTX Health Care
- Exchange
- ALXO Nasdaq
- ENTX Nasdaq
- Market Cap
- ALXO 74.4M
- ENTX 67.2M
- IPO Year
- ALXO 2020
- ENTX 2018
- Fundamental
- Price
- ALXO $1.51
- ENTX $1.70
- Analyst Decision
- ALXO Strong Buy
- ENTX Strong Buy
- Analyst Count
- ALXO 6
- ENTX 1
- Target Price
- ALXO $14.20
- ENTX $10.00
- AVG Volume (30 Days)
- ALXO 842.0K
- ENTX 131.8K
- Earning Date
- ALXO 11-07-2024
- ENTX 11-08-2024
- Dividend Yield
- ALXO N/A
- ENTX N/A
- EPS Growth
- ALXO N/A
- ENTX N/A
- EPS
- ALXO N/A
- ENTX N/A
- Revenue
- ALXO N/A
- ENTX $99,000.00
- Revenue This Year
- ALXO N/A
- ENTX N/A
- Revenue Next Year
- ALXO N/A
- ENTX N/A
- P/E Ratio
- ALXO N/A
- ENTX N/A
- Revenue Growth
- ALXO N/A
- ENTX 607.14
- 52 Week Low
- ALXO $1.19
- ENTX $0.52
- 52 Week High
- ALXO $17.83
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- ALXO 54.25
- ENTX 48.78
- Support Level
- ALXO $1.19
- ENTX $1.54
- Resistance Level
- ALXO $1.60
- ENTX $1.69
- Average True Range (ATR)
- ALXO 0.11
- ENTX 0.10
- MACD
- ALXO 0.04
- ENTX 0.00
- Stochastic Oscillator
- ALXO 72.73
- ENTX 57.60
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.